Developer docs
API playgroundTry for free, no card

Search company profiles

Sofar

Full company profile

uuid000e42s

Namestring
Sofar
Legal namestring
Sofar S.p.A.
Websiteurl
sofarfarm.it
Company typeenum
Private
Founded yearint
1968
Descriptiontext

Sofar S.p.A. is an Italian pharmaceutical manufacturer, founded in 1968 and headquartered in Bologna, that has historically developed and produced its own line of products including dietary supplements and medical devices. Effective February 1, 2023, the company underwent a partial demerger (scissione parziale) whereby its commercial branch — including customer relationships, product brands, and digital properties — was transferred to its controlling parent company, Alfasigma S.p.A.

Following this restructuring, Sofar S.p.A. continues to operate as a legally distinct entity but is now dedicated exclusively to pharmaceutical production and Contract Development and Manufacturing Organization (CDMO) services for third-party pharmaceutical clients. The company's business model has therefore shifted from an integrated branded-products manufacturer to a pure B2B contract manufacturer operating under the Alfasigma S.p.A. corporate umbrella.

The entity is structured as an Italian private limited company (S.p.A.) with a single headcount band of 251–500 employees and no publicly disclosed revenue, pricing model, or product-level information in the available sources. Core technology is centered on pharmaceutical manufacturing capabilities rather than software, AI, or digital platforms, and the company has no disclosed marketing or distribution channels, patents, awards, partnerships, or leadership team details beyond a single CEO reference.

Short descriptiontext

Sofar S.p.A. is an Italian pharmaceutical CDMO and subsidiary of Alfasigma S.p.A., focused exclusively on contract manufacturing and production services for pharmaceutical clients following a February 2023 partial demerger from its parent.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersPetaluma, United States
HQ citystring
Petaluma
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, contract development manufacturing, CDMO services, drug production services, pharmaceutical contract services
Industry1 code
1Drug Substance–Drug Product Integrated CDMO
CodeHLAGABAGPrimaryYes
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Contract Manufacturing
No data
Cost components4 values
Personnel, Operations, Supply Chain, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Sofar S.p.A. operates as a pharmaceutical Contract Development and Manufacturing Organization (CDMO), providing dedicated production and contract manufacturing services to pharmaceutical industry clients. Following a partial demerger effective February 1, 2023, the commercial branch was transferred to parent company Alfasigma S.p.A., and Sofar S.p.A. now focuses exclusively on production and CDMO activities.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

No product information available in the provided sources. The available source indicates that Sofar S.p.A. operates as a production and Contract Development and Manufacturing Organization (CDMO), but no specific products, brand names, or service offerings are detailed in the aggregated content.

Product and service1 record
1Pharmaceutical CDMO and Production Services
CategoryPharmaceutical Contract Manufacturing
Description

Contract Development and Manufacturing Organization (CDMO) services providing pharmaceutical production and manufacturing capabilities to pharmaceutical company clients. Following the February 2023 partial demerger, Sofar S.p.A. focuses exclusively on this service offering.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
1Recipharm
TypeDirect peer
Description

European-headquartered CDMO offering solid-dose, sterile, and API manufacturing services to pharma clients. Directly comparable to Sofar on geography (Europe), service mix (small-molecule CDMO), and target customer base (mid-market and generics pharma).

2Siegfried Holding
TypeDirect peer
Description

Swiss-listed CDMO providing API and finished drug product manufacturing for branded and generic pharma. Comparable to Sofar in integrated drug-substance/drug-product CDMO scope and European mid-market positioning.

3Aenova Group
TypeDirect peer
Description

German-headquartered CDMO offering solid, semi-solid, sterile, and biologic manufacturing services. Comparable to Sofar on pharmaceutical contract manufacturing focus, European footprint, and broad dosage-form capabilities.

4Fareva
TypeDirect peer
Description

Privately-held French CDMO providing API, drug product, and packaging services to pharmaceutical clients. Comparable to Sofar in private mid-sized European CDMO profile and broad small-molecule manufacturing scope.

5Delpharm
TypeDirect peer
Description

French CDMO offering contract manufacturing of solid, liquid, sterile, and biologic drug products for European pharma sponsors. Comparable to Sofar on European generics-focused CDMO positioning and similar mid-market scale.

6BSP Pharmaceuticals
TypeDirect peer
Description

Italian CDMO specializing in sterile injectable and oncology product manufacturing. Closely comparable to Sofar on Italian geography, pharmaceutical contract manufacturing, and similar mid-sized European CDMO profile.

7Olon Group
TypeDirect peer
Description

Italian API manufacturer and CDMO with a strong generics-focused small-molecule portfolio. Comparable to Sofar in Italian origin, API and drug-product CDMO capabilities, and service to generics pharma sponsors.

8Corden Pharma
TypeDirect peer
Description

Global CDMO offering API synthesis, drug product manufacturing, and packaging across multiple modalities. Comparable to Sofar in integrated small-molecule CDMO scope, though operating at a larger scale.

9Alfasigma S.p.A.
TypeBroad incumbent
Description

Parent company of Sofar S.p.A. and an Italian specialty pharmaceutical group with both proprietary branded products and contract manufacturing activities. Comparable as both the strategic owner and an adjacent incumbent in pharmaceutical manufacturing with broader commercial capabilities than Sofar's now-focused CDMO scope.

10Lonza Group
TypeBroad incumbent
Description

Global CDMO leader offering small-molecule API, biologics, and cell-and-gene therapy manufacturing services. Comparable to Sofar as a CDMO operating in the same end markets, though at vastly greater scale, geographic reach, and modality breadth.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sofar

Pharmaceutical Contract Manufacturingsofarfarm.it

Sofar S.p.A. is an Italian pharmaceutical CDMO and subsidiary of Alfasigma S.p.A., focused exclusively on contract manufacturing and production services for pharmaceutical clients following a February 2023 partial demerger from its parent.

What Sofar does

Sofar S.p.A. is an Italian pharmaceutical manufacturer, founded in 1968 and headquartered in Bologna, that has historically developed and produced its own line of products including dietary supplements and medical devices. Effective February 1, 2023, the company underwent a partial demerger (scissione parziale) whereby its commercial branch — including customer relationships, product brands, and digital properties — was transferred to its controlling parent company, Alfasigma S.p.A.

Following this restructuring, Sofar S.p.A. continues to operate as a legally distinct entity but is now dedicated exclusively to pharmaceutical production and Contract Development and Manufacturing Organization (CDMO) services for third-party pharmaceutical clients. The company's business model has therefore shifted from an integrated branded-products manufacturer to a pure B2B contract manufacturer operating under the Alfasigma S.p.A. corporate umbrella.

The entity is structured as an Italian private limited company (S.p.A.) with a single headcount band of 251–500 employees and no publicly disclosed revenue, pricing model, or product-level information in the available sources. Core technology is centered on pharmaceutical manufacturing capabilities rather than software, AI, or digital platforms, and the company has no disclosed marketing or distribution channels, patents, awards, partnerships, or leadership team details beyond a single CEO reference.

Sofar firmographics

Firmographics
Name
Sofar
Legal name
Sofar S.p.A.
Website
https://sofarfarm.it
Company type
Private
Founded year
1968
Operating status
Operating
Headcount range
251–500 employees
Short description
Sofar S.p.A. is an Italian pharmaceutical CDMO and subsidiary of Alfasigma S.p.A., focused exclusively on contract manufacturing and production services for pharmaceutical clients following a February 2023 partial demerger from its parent.
Ownership category
akta.pro rank

Sofar industry classification

Industry
Product category
Pharmaceutical Contract Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro primary industry
Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

Keywords

  • Pharmaceutical manufacturing
  • Contract development manufacturing
  • CDMO services
  • Drug production services
  • Pharmaceutical contract services

Where Sofar is headquartered

Location

Headquarters

HQ city
Petaluma
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Sofar business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Supply Chain, Technology or R&D

Sofar product offering

Product offering

Core offering

Sofar S.p.A. operates as a pharmaceutical Contract Development and Manufacturing Organization (CDMO), providing dedicated production and contract manufacturing services to pharmaceutical industry clients. Following a partial demerger effective February 1, 2023, the commercial branch was transferred to parent company Alfasigma S.p.A., and Sofar S.p.A. now focuses exclusively on production and CDMO activities.

Product overview

No product information available in the provided sources. The available source indicates that Sofar S.p.A. operates as a production and Contract Development and Manufacturing Organization (CDMO), but no specific products, brand names, or service offerings are detailed in the aggregated content.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pharmaceutical CDMO and Production Services Contract Development and Manufacturing Organization (CDMO) services providing pharmaceutical production and manufacturing capabilities to pharmaceutical company clients. Following the February 2023 partial demerger, Sofar S.p.A. focuses exclusively on this service offering.

Companies that use Sofar

Customer profile

Segments1 record

Ideal customer profiles1 record

Sofar technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Sofar partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights1 record

Sofar competitors and assessment

Company assessment

Direct peers

  • Recipharm: European-headquartered CDMO offering solid-dose, sterile, and API manufacturing services to pharma clients. Directly comparable to Sofar on geography (Europe), service mix (small-molecule CDMO), and target customer base (mid-market and generics pharma).
  • Siegfried Holding: Swiss-listed CDMO providing API and finished drug product manufacturing for branded and generic pharma. Comparable to Sofar in integrated drug-substance/drug-product CDMO scope and European mid-market positioning.
  • Aenova Group: German-headquartered CDMO offering solid, semi-solid, sterile, and biologic manufacturing services. Comparable to Sofar on pharmaceutical contract manufacturing focus, European footprint, and broad dosage-form capabilities.
  • Fareva: Privately-held French CDMO providing API, drug product, and packaging services to pharmaceutical clients. Comparable to Sofar in private mid-sized European CDMO profile and broad small-molecule manufacturing scope.
  • Delpharm: French CDMO offering contract manufacturing of solid, liquid, sterile, and biologic drug products for European pharma sponsors. Comparable to Sofar on European generics-focused CDMO positioning and similar mid-market scale.
  • BSP Pharmaceuticals: Italian CDMO specializing in sterile injectable and oncology product manufacturing. Closely comparable to Sofar on Italian geography, pharmaceutical contract manufacturing, and similar mid-sized European CDMO profile.
  • Olon Group: Italian API manufacturer and CDMO with a strong generics-focused small-molecule portfolio. Comparable to Sofar in Italian origin, API and drug-product CDMO capabilities, and service to generics pharma sponsors.
  • Corden Pharma: Global CDMO offering API synthesis, drug product manufacturing, and packaging across multiple modalities. Comparable to Sofar in integrated small-molecule CDMO scope, though operating at a larger scale.

Broad incumbents

  • Alfasigma S.p.A. Parent company of Sofar S.p.A. and an Italian specialty pharmaceutical group with both proprietary branded products and contract manufacturing activities. Comparable as both the strategic owner and an adjacent incumbent in pharmaceutical manufacturing with broader commercial capabilities than Sofar's now-focused CDMO scope.
  • Lonza Group: Global CDMO leader offering small-molecule API, biologics, and cell-and-gene therapy manufacturing services. Comparable to Sofar as a CDMO operating in the same end markets, though at vastly greater scale, geographic reach, and modality breadth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Sofar financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sofar leadership team

Management profile

Number of profiles

Profiles2 records

Sofar funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sofar M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sofar

What does Sofar do?

Sofar S.p.A. operates as a pharmaceutical Contract Development and Manufacturing Organization (CDMO), providing dedicated production and contract manufacturing services to pharmaceutical industry clients. Following a partial demerger effective February 1, 2023, the commercial branch was transferred to parent company Alfasigma S.p.A., and Sofar S.p.A. now focuses exclusively on production and CDMO activities.

When was Sofar founded?

Sofar was founded in 1968. It employs 251 to 500 people.

Where is Sofar based?

Sofar is headquartered in Petaluma, United States, in the North America region.

Who are Sofar's main competitors?

Direct peers on record are Recipharm, Siegfried Holding, Aenova Group, Fareva, Delpharm, BSP Pharmaceuticals, Olon Group and Corden Pharma. Broad incumbents are Alfasigma S.p.A. and Lonza Group.

Does Sofar have an API?

No public API is recorded for Sofar.

What industry is Sofar in?

Sofar's product category is Pharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerFine Foods & Pharmaceuticals N.T.M. S.p.A. (BIT: FF) signed a binding agreement to acquire SOFAR S.p.A. from Alfasigma S.p.A. for an enterprise value of ?27 million.Fine Foods & Pharmaceuticals N.T.M. S.p.A. signed a binding agreement to acquire SOFAR S.p.A. from Alfasigma S.p.A. for an enterprise value of €27 million. SOFAR reported revenue of €31.8 million, net income of €4.4 million, and EBITDA of €8.9 million for the period ending December 31, 2025. The deal is expected to close by the first half of June 2026, subject to standard conditions.PR NewswireALFASIGMA ACQUIRES THE ENTIRE SHARE CAPITAL OF SOFAR, AN ITALIAN PHARMACEUTICAL COMPANYAlfasigma S.p.A. has completed its acquisition of SOFAR S.p.A., an Italian pharmaceutical company specializing in gastroenterology, with the transaction successfully closing in October 2022 after being announced in August. SOFAR brings 54 years of expertise in gastroenterology, over €100 million in turnover, 150 marketed references across 10 therapeutic areas, and 300 employees, along with a microbiota research center developed through the Kilometro Rosso Science and Technology Park in Bergamo. The combined entity aims to more than double revenues within 10 years by leveraging complementary product portfolios and expanded international market potential in the gastrointestinal segment.PR Newswire APACALFASIGMA ACQUIRES SOFAR'S ENTIRE SHARE CAPITAL, AN ITALIAN PHARMACEUTICAL COMPANYAlfasigma S.p.A. has completed the acquisition of SOFAR S.p.A., an Italian pharmaceutical company, finalizing the transaction originally launched in August 2022. The deal integrates SOFAR's gastroenterology portfolio and R&D capabilities into Alfasigma's operations, aiming to consolidate their market position and drive international expansion.AlfasigmaALFASIGMA ACQUIRES THE ENTIRE SHARE CAPITAL OF SOFAR, AN ITALIAN PHARMACEUTICAL COMPANYAlfasigma has completed the acquisition of SOFAR, an Italian pharmaceutical company, finalizing the transaction originally announced in August. This move consolidates Alfasigma's leadership in the gastrointestinal sector and microbiota research while integrating SOFAR's product portfolio to support international expansion. The combined entity aims to double revenues over ten years by leveraging synergies in R&D and market presence.The Pharma LetterAlfasigma to acquire fellow Italian drugmaker SofarItalian drugmaker Alfasigma has signed an agreement to acquire the entire share capital of fellow Italian pharmaceutical company Sofar. The transaction involves Sofar, which possesses over half a century of operational history in the research, production, and marketing of drugs, medical devices, and food supplements.AlfasigmaALFASIGMA ANNOUNCES THE AGREEMENT FOR THE ACQUISITION OF 100% OF SOFAR, ITALIAN PHARMACEUTICAL COMPANYAlfasigma S.p.A. has signed an agreement to acquire 100% of the share capital of Italian pharmaceutical company SOFAR S.p.A., with completion expected in October 2022. The transaction consolidates Alfasigma's leadership in the gastrointestinal area and adds SOFAR’s product portfolio, which generated over 113 million euros in turnover in 2021. This strategic move aims to expand both companies' presence in Italy and international markets through integrated research and production capabilities.PR NewswireALFASIGMA ANNONCE L'ACCORD POUR L'ACQUISITION DE 100 % DE SOFAR, SOCIÉTÉ PHARMACEUTIQUE ITALIENNEAlfasigma S.p.A. has signed an agreement to acquire 100% of the shares of SOFAR S.p.A., an Italian pharmaceutical company specializing in gastro-intestinal products and microbiote research. The acquisition, valued based on SOFAR's 2021 revenue of over 113 million euros, is expected to be finalized in October 2022 to expand Alfasigma's product portfolio and international presence.PR NewswireSOFAR Americas' AminoAlta Probiotic Achieves Self-Affirmed GRAS StatusSOFAR Americas announced that its AminoAlta probiotic plant-protein booster has achieved full self-affirmed GRAS status, confirming its safety for use in dietary supplements. AminoAlta combines two Lactobacillus paracasei strains designed to enhance the body's absorption of amino acids from plant proteins, with the first strain receiving GRAS status in 2018 and the second in Spring 2021. The timing aligns with projected growth in the plant-based protein market, which is expected to reach $23.4 billion in the U.S. by 2027.PR NewswireSOFAR Americas Introduces Innovia Probiotic Micro-Shots for KidsSOFAR Americas, the U.S. subsidiary of Italy's SOFAR S.p.A., announced on July 22, 2020 the launch of Innovia KIDS, a probiotic micro-shot supplement for children ages 4+. The product features the company's patented LP-DG® probiotic strain combined with vitamins D3 and B, delivered through a unique cap-activated micro-shot system that keeps one billion live cultures stable without refrigeration until consumption. The launch marks the expansion of the Innovia Probiotics brand into the pediatric digestive health market in the United States.PR NewswireTechnical Reports on Medical Supplies Stocks -- Endologix, Becton, Dickinson, Antares Pharma, and TransEnterixStock-Callers.com released research reports covering four medical supply companies: Endologix, Becton Dickinson, Antares Pharma, and TransEnterix. The report highlights specific corporate developments for each firm, including Endologix lifting a shipment hold on its AAA systems, Becton Dickinson launching new syringes and receiving a rating downgrade, Antares Pharma submitting a drug application to the FDA, and TransEnterix securing a €5 million investment from SOFAR S.p.A.